Italia markets open in 6 hours 50 minutes

Intellia Therapeutics, Inc. (0JBU.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
45,74+3,82 (+9,11%)
Alla chiusura: 06:19PM GMT
Schermo intero
Chiusura precedente41,92
Aperto0,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume20
Media VolumeN/D
Capitalizzazione21,855M
Beta (5 anni mensile)1,86
Rapporto PE (ttm)N/D
EPS (ttm)-5,06
Prossima data utili22 feb 2023 - 27 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

    Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in people with hereditary angioedema (HAE) CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developin

  • GlobeNewswire

    Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

    Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023Submit IND application for NTLA-2002 for the treatment of hereditary angioedema (HAE) and initiate global Phase 2 study in 1H 2023P

  • GlobeNewswire

    Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common